IMRX on Nasdaq

Immuneering Corp

American pharmaceutical preparations company based in Cambridge.

Price unavailable

Last updated Oct 18, 2026.

Overview

-$56.0MNet income, fiscal 2025²

Compare with Vyome Holdings, Inc, Allarity Therapeutics, Inc. or Edesa Biotech, Inc., or pick any stock.

TickerIMRX on Nasdaq
IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE³
Business address245 Main Street, Second Floor, Cambridge, Ma 02142³
Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company³

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-100.0%Revenue growth, 2023⁴

-59.0%Return on equity²

-$49.3MFree cash flow⁵

Financial statements

Revenue⁶⁷⁴$0 in 2023

Gross profit⁶⁷⁴$0 in 2023

Operating income⁶⁷⁴⁵-$58.4M in 2023+242% since 2020

Net income⁶⁷⁴⁵-$53.5M in 2023+214% since 2020

Every line of the income statement as filed: the last 2 fiscal years, latest first.²

Period ending	2025-12-31	2024-12-31
Research and development	$42.0M	$48.0M
General and administrative	$17.3M	$16.1M
Amortization of intangible asset	$29.3K	$29.3K
Total operating expenses	$59.4M	$64.1M
Loss from operations	-$59.4M	-$64.1M
Interest income	$3.0M	$2.6M
Other income, net	$311.7K	$441.5K
Net loss	-$56.0M	-$61.0M
Net loss per share attributable to common stockholders, basic (in dollars per share)	-$1.27	-$2.04
Net loss per share attributable to common stockholders, diluted (in dollars per share)	-$1.27	-$2.04
Weighted-average common shares outstanding, basic (in shares)	44.0M shares	30.0M shares
Weighted-average common shares outstanding, diluted (in shares)	44.0M shares	30.0M shares
Unrealized gain from marketable securities	$81.3K	$778
Comprehensive Loss	-$55.9M	-$61.0M

Total assets⁶⁷⁴⁵$102.6M in 2023+167% since 2020

Total liabilities⁶⁷⁴⁵$12.0M in 2023+329% since 2020

Shareholders’ equity⁶⁷⁴⁵²$90.6M in 2023

Cash⁶⁷⁴⁵$59.4M in 2023+331% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.²

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$128.6M	$36.1M
Marketable securities, current	$44.2M	$0
Prepaids and other current assets	$3.4M	$3.4M
Total current assets	$176.2M	$39.6M
Marketable securities, non-current	$44.2M	$0
Property and equipment, net	$938.5K	$1.1M
Goodwill	$6.7M	$6.7M
Intangible asset, net	$321.1K	$350.4K
Right-of-use assets, net	$3.3M	$3.7M
Other assets	$283.6K	$1.3M
Total assets	$232.0M	$52.7M
Accounts payable	$1.5M	$2.0M
Accrued expenses	$7.8M	$5.0M
Other liabilities	$291.5K	$233.7K
Lease liabilities	$397.1K	$338.4K
Total current liabilities	$10.1M	$7.5M
Lease liabilities, net of current portion	$3.4M	$3.8M
Total liabilities	$13.5M	$11.3M
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; 0 shares issued or outstanding at December 31, 2025 and December 31, 2024	$0	$0
Additional paid-in capital	$498.7M	$265.7M
Accumulated other comprehensive income	$81.3K	$0
Accumulated deficit	-$280.3M	-$224.3M
Total stockholders' equity	$218.5M	$41.4M	$90.6M
Total liabilities and stockholders' equity	$232.0M	$52.7M
Preferred stock, par value per share (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	10.0M shares	10.0M shares
Preferred stock, shares issued (in shares)	0 shares	0 shares
Preferred stock, shares outstanding (in shares)	0 shares	0 shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash and cash equivalents	$128.6M	$36.1M
Marketable securities, current	$44.2M	$0
Prepaids and other current assets	$3.4M	$3.4M
Total current assets	$176.2M	$39.6M
Marketable securities, non-current	$44.2M	$0
Property and equipment, net	$938.5K	$1.1M
Goodwill	$6.7M	$6.7M
Intangible asset, net	$321.1K	$350.4K
Right-of-use assets, net	$3.3M	$3.7M
Other assets	$283.6K	$1.3M
Total assets	$232.0M	$52.7M
Accounts payable	$1.5M	$2.0M
Accrued expenses	$7.8M	$5.0M
Other liabilities	$291.5K	$233.7K
Lease liabilities	$397.1K	$338.4K
Total current liabilities	$10.1M	$7.5M
Lease liabilities, net of current portion	$3.4M	$3.8M
Total liabilities	$13.5M	$11.3M
Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and December 31, 2024; 0 shares issued or outstanding at December 31, 2025 and December 31, 2024	$0	$0
Additional paid-in capital	$498.7M	$265.7M
Accumulated other comprehensive income	$81.3K	$0
Accumulated deficit	-$280.3M	-$224.3M
Total stockholders' equity	$218.5M	$41.4M	$90.6M
Total liabilities and stockholders' equity	$232.0M	$52.7M
Preferred stock, par value per share (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized (in shares)	10.0M shares	10.0M shares
Preferred stock, shares issued (in shares)	0 shares	0 shares
Preferred stock, shares outstanding (in shares)	0 shares	0 shares

Cash from operations⁶⁷⁴⁵-$49.0M in 2023+235% since 2020

Capital spending⁶⁷⁴⁵$342.7K in 2023+542% since 2020

Free cash flow⁶⁷⁴⁵-$49.3M in 2023+236% since 2020

Every line of the cash flow as filed: the last 2 fiscal years, latest first.²

Period ending	2025-12-31	2024-12-31
Net loss	-$56.0M	-$61.0M
Depreciation and amortization expense	$324.5K	$355.8K
Reduction in carrying amount of right-of-use assets	$345.1K	$328.4K
Amortization of intangibles	$29.3K	$29.3K
Stock-based compensation expense	$6.3M	$6.5M
Net accretion of discount on marketable securities	-$155.7K	-$259.2K
Loss on disposal of fixed assets	$2.1K	$6.8K
Prepaid expenses and other current assets	$491.8K	-$24.9K
Other assets	$1.1M	-$261.3K
Accounts payable	-$400.8K	-$112.1K
Accrued expenses	$2.9M	-$200.8K
Lease liabilities	-$338.4K	-$300.1K
Other liabilities	$57.8K	-$26.1K
Net cash used in operating activities	-$45.3M	-$55.0M
Purchases of property and equipment	-$142.2K	-$84.9K
Purchases of marketable securities	-$88.6M	-$5.4M
Maturities of marketable securities	$0	$31.9M
Net cash (used in) provided by investing activities	-$88.7M	$26.4M
Payment of offering costs	-$3.7M	-$41.0K
Proceeds from exercise of stock options	$368.5K	$732.5K
Proceeds from employee stock purchase plan	$421.9K	$374.7K
Net cash provided by financing activities	$226.6M	$5.3M
Net increase (decrease) in cash and cash equivalents	$92.5M	-$23.3M
Deferred offering costs in accounts payable/accrued expenses	$45.0K	$0
Cashless exercise of prefunded warrants	$1.1K	$0

Compare Immuneering Corp with another company

Leadership

Who has led Immuneering Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

Benjamin J. Zeskind2021–now

President

Benjamin J. Zeskind2021–now

Chief financial officer

2025

Chief executive officerBenjamin J. Zeskind Jul 29, 2021 to now¹²
PresidentBenjamin J. Zeskind Jul 29, 2021 to now¹²
Chief financial officerAndrew Gengos Jul 16, 2026 to now¹³
Chief financial officerBiren Amin Jul 29, 2021 to May 12, 2022¹⁴

Board members and other officers (13)

Chief Medical OfficerIgor Matushansky Mar 24, 2025 to now¹⁵
Chief Business OfficerHarold Eugene Brakewood Apr 3, 2023 to now¹⁶
Vice President, FinanceMallory Morales Aug 11, 2022 to now¹⁷
Chief People OfficerLeah R. Neufeld Oct 20, 2022 to now¹⁸
Chief Scientific OfficerBrett Matthew Hall Jul 29, 2021 to now¹⁹
Chief Medical OfficerScott Barrett Jul 29, 2021 to Feb 17, 2023²⁰
Board memberThomas J. Schall Mar 12, 2024 to now²¹
Board memberDiana Hausman Jan 18, 2022 to now²²
Board memberAnn E. Berman Jul 29, 2021 to now²³
Board memberBenjamin J. Zeskind Jul 29, 2021 to now¹²
Board memberPeter Feinberg Jul 29, 2021 to now²⁴
Board memberRobert J. Carpenter Jul 29, 2021 to now²⁵
General counselMichael Bookman Jul 29, 2021 to now²⁶

Timeline

Jul 29, 2021New chief executive Benjamin J. Zeskind becomes CEO¹²

Filings

265 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 46 major events, 137 insider forms, 28 large holders, 1 private raises, 33 other. The latest 20:

Aug 5, 202610-Q EDGAR
Aug 5, 20268-K EDGAR
Jul 28, 2026SCHEDULE 13G EDGAR
Jul 17, 20264 EDGAR
Jul 16, 20263 EDGAR
Jun 24, 20264 EDGAR
Jun 16, 20264 EDGAR
Jun 15, 20268-K EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20264 EDGAR
Jun 11, 20268-K EDGAR
Jun 1, 20268-K EDGAR
May 15, 202610-Q EDGAR
May 15, 20268-K EDGAR
Apr 20, 2026DEFA14A EDGAR
Apr 20, 2026DEF 14A EDGAR
Mar 17, 20264 EDGAR

The 265 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 28 such filings since October 2021, the latest 10:

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

Aug 26, 2025Raised $25 million in a private offering of equity Form D: 9 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Fmr LLC	9,704,610	$48.4M	0.0%	+6,672
BlackRock, Inc.	4,374,020	$21.8M	0.0%	+2,866,762
Sanofi	2,708,559	$13.5M	2.5%	No change
Vanguard Capital Management LLC	2,286,434	$11.4M	0.0%	−1,907
Geode Capital Management, LLC	1,370,750	$6.8M	0.0%	+732,806
State Street Corp	1,001,995	$5.0M	0.0%	+733,475
DCF Advisers, LLC	790,000	$3.9M	1.0%	+648,538
Marshall Wace, Llp	731,897	$3.7M	0.0%	−1,264,688
Connor, Clark & Lunn Investment Management Ltd.	601,255	$3.0M	0.0%	+200,892
Alethea Capital Management, LLC	472,935	$2.4M	1.0%	+450,000
Summit Financial, LLC	452,264	$2.3M	0.0%	+75,515
UBS Group AG	448,857	$2.2M	0.0%	+72,573
Nuveen, LLC	438,362	$2.2M	0.0%	New
Northern Trust Corp	436,992	$2.2M	0.0%	+319,326
Levin Capital Strategies, L.P.	414,000	$2.1M	0.1%	+404,000
Citadel Advisors LLC	386,411	$1.9M	0.0%	−60,867
Vanguard Fiduciary Trust Co	360,764	$1.8M	0.0%	+38,726
Vanguard Portfolio Management LLC	359,085	$1.8M	0.0%	New
Millennium Management LLC	330,402	$1.6M	0.0%	−772,310
Burkehill Global Management, LP	300,000	$1.5M	0.1%	No change
Two Sigma Investments, LP	288,420	$1.4M	0.0%	+43,649
Morgan Stanley	226,491	$1.1M	0.0%	−69,576
Occam Crest Management LP	278,498	$1.1M	0.6%	−266,600
D. E. Shaw & Co., Inc.	203,663	$1.0M	0.0%	New
Charles Schwab Investment Management Inc	167,901	$837.8K	0.0%	+130,557

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARImmuneering Corp filings on SEC EDGAR
2
SEC EDGARImmuneering Corp 10-K for fiscal 2025
3
SEC EDGARImmuneering Corp filings on SEC EDGAR
4
SEC EDGARImmuneering Corp 10-K for fiscal 2023
5
SEC EDGARImmuneering Corp 10-K for fiscal 2023
6
SEC EDGARImmuneering Corp 10-K for fiscal 2020
7
SEC EDGARImmuneering Corp 10-K for fiscal 2021
8
SEC EDGARImmuneering Corp 10-Q for fiscal 2025
9
SEC EDGARImmuneering Corp 10-Q for fiscal 2025
10
SEC EDGARImmuneering Corp 10-Q for fiscal 2026
11
SEC EDGARImmuneering Corp 10-Q for fiscal 2025
12
SEC EDGARBenjamin J. Zeskind, Chief executive officer
13
SEC EDGARAndrew Gengos, Chief financial officer
14
SEC EDGARBiren Amin, Chief financial officer
15
SEC EDGARIgor Matushansky, Chief Medical Officer
16
SEC EDGARHarold Eugene Brakewood, Chief Business Officer
17
SEC EDGARMallory Morales, Vice President, Finance
18
SEC EDGARLeah R. Neufeld, Chief People Officer
19
SEC EDGARBrett Matthew Hall, Chief Scientific Officer
20
SEC EDGARScott Barrett, Chief Medical Officer
21
SEC EDGARThomas J. Schall, Board member
22
SEC EDGARDiana Hausman, Board member
23
SEC EDGARAnn E. Berman, Board member
24
SEC EDGARPeter Feinberg, Board member
25
SEC EDGARRobert J. Carpenter, Board member
26
SEC EDGARMichael Bookman, General counsel